SAR3419 in Acute Lymphoblastic Leukemia

• Status: Terminated
• Trial end date: 2014-05-01

Summary

Primary Objective:

Participants achieving an Objective Response Rate

Secondary Objectives:

• Response duration

• Progression Free Survival

• Minimal residual disease

• Safety

• Pharmacokinetics

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Maytansine